ReviewFrontiers in aging neuroscience2025
Improving recognition and management of inpatient delirium in Parkinson's disease: evidence review and implications for clinical care.
Review in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delirium is an acute disturbance of attention, arousal, and cognition that fluctuates in severity and is a common yet under recognized complication in hospitalized patients with Parkinson's disease. In Parkinson's disease, symptoms such as rigidity, bradykinesia, hallucinations, and slowed thinking overlap with the clinical features of delirium, which can obscure its onset in hospitalized patients. Variability in diagnostic criteria further complicates accurate recognition and prevalence estimates. This mini review summarizes current evidence on the prevalence, risk factors, and consequences of delirium in Parkinson's disease (PD) and its associations with mortality and institutionalization. A total of 61 reports published between 1990 and 2025 were included across five domains: delirium diagnosis and prevalence, delirium subtypes, PD-specific delirium rates, risk factors and prevention, and treatment considerations. Foundational evidence reviews and official diagnostic documents (e.g., ICD-10, ICD-11, DSM criteria) were also incorporated as they remain internationally recognized standards for delirium diagnosis. Scholarly studies were appraised using the Joanna Briggs Institute (JBI) Critical Appraisal Checklists, with overall evidence quality judged to be moderate to high, while official diagnostic and guideline documents were considered high-quality based on their authoritative, consensus-driven development. Standardized clinical strategies for hospital management remain limited, but the available evidence supports the use of tailored approaches. We present evidence-based implications for clinical care aligned with the Parkinson's Foundation Hospital Care Standards to improve recognition, prevention, and treatment. We emphasize the need for critical evaluation, methodological consistency, and acknowledgment of the dynamic care challenges posed by delirium in Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.